Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Heart Failure

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Chemical compound and disease context of Heart Failure

The results of the ongoing trials examining the effect of levosimendan on mortality in patients with heart failure will hopefully resolve the controversy as to whether levosimendan is superior to classic inotropic agents for the treatment of severe heart failure [1].
Expression of four proteins, glyceraldehyde-3-phosphate dehydrogenase, alphaB-crystallin, peroxiredoxin 2, and isocitrate dehydrogenase, was linked to echographic parameters according to heart failure severity [2].

Gene context of Heart Failure

Adrenal gland-specific GRK2 inhibition reversed alpha2AR dysregulation in heart failure, resulting in lowered plasma catecholamine levels, improved cardiac betaAR signaling and function, and increased sympatholytic efficacy of a alpha2AR agonist [3].
ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to beta-blocker therapy of heart failure patients [4].
Two SNPs (IVS-4 G/A and Lys198Asn) in the endothelin-1 gene, however, predicted time to the combined endpoint of heart failure hospitalization or all-cause death in bucindolol-treated patients [5].

References

Levosimendan: beyond its simple inotropic effect in heart failure. Antoniades, C., Tousoulis, D., Koumallos, N., Marinou, K., Stefanadis, C. Pharmacol. Ther. (2007) [Pubmed]
Proteomic analysis of left ventricular remodeling in an experimental model of heart failure. Cieniewski-Bernard, C., Mulder, P., Henry, J.P., Drobecq, H., Dubois, E., Pottiez, G., Thuillez, C., Amouyel, P., Richard, V., Pinet, F. J. Proteome Res. (2008) [Pubmed]
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A.D., Koch, W.J. Nat. Med. (2007) [Pubmed]
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Lobmeyer, M.T., Gong, Y., Terra, S.G., Beitelshees, A.L., Langaee, T.Y., Pauly, D.F., Schofield, R.S., Hamilton, K.K., Herbert Patterson, J., Adams, K.F., Hill, J.A., Aranda, J.M., Johnson, J.A. Pharmacogenet. Genomics (2007) [Pubmed]
Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Taylor, M.R., Slavov, D., Humphrey, K., Zhao, L., Cockroft, J., Zhu, X., Lavori, P., Bristow, M.R., Mestroni, L., Lazzeroni, L.C. Pharmacogenet. Genomics (2009) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share